

200005274-6

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 49/00	A2	(11) International Publication Number: WO 99/58162 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/US99/06826 (22) International Filing Date: 29 March 1999 (29.03.99) (30) Priority Data: 60/080,150 31 March 1998 (31.03.98) US 60/112,715 18 December 1998 (18.12.98) US (71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US). (72) Inventors: RAJOPADHYE, Miland; 21 Honeysuckle Road, Westford, MA 01886 (US). EDWARDS, D., Scott; 123 Farms Drive, Burlington, MA (US). HARRIS, Thomas, D.; 56 Zion Hill Road, Samel, NH 03079 (US). HEMINWAY, Stuart, J.; 21 Fidler Terrace, Lowell, MA 01850 (US). LIU, Shuang; 17 Judith Road, Chelmsford, MA 01824 (US). SINGH, Prahlad, R.; 144 Charlton Street, Arlington, MA 02174 (US). (74) Agent: VANCE, David, H.; Du Pont Pharmaceuticals Com- pany, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS		
(57) Abstract The present invention describes novel compounds of the formula: $(Q)_d-L_n-C_h$, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.		